Johnson & Johnson (JNJ) is set to release its Q3 earnings results on Tuesday, October 15th, before the market opens. Investors and analysts are keen to see how the healthcare giant has performed amidst ongoing challenges and opportunities within its MedTech and pharmaceutical divisions. The earnings report is expected to shed light on the company’s profitability, revenue trends, and strategic progress.
Is now the time to buy Johnson & Johnson? Access our full analysis report here, it’s free.
Expected Q3 Earnings Report of Johnson & Johnson:
Analysts anticipate Johnson & Johnson will report earnings per share (EPS) of $2.21, reflecting a 16.9% year-over-year (Y/Y) decline. Despite the drop in profit, the company is expected to post revenue of $22.17 billion, representing a 3.8% Y/Y increase. This growth is likely fueled by its MedTech division, which has been a focal point as the company navigates a shifting landscape. Johnson & Johnson has faced headwinds, particularly from patent expirations and legal challenges, but its robust product pipeline and diversified portfolio continue to support its market presence.
Investing is all about making informed decisions, and now you can do it for less. Get 70% off Stock Target Advisor and start optimizing your portfolio today. Grab your discount now!
Stock Target Advisor’s Analysis on Johnson & Johnson:
According to Stock Target Advisor, Johnson & Johnson’s stock is rated as Slightly Bullish, reflecting a positive outlook. The analysis is based on nine positive signals and four negative signals. The stock’s target price is set at $169, with a projected price change of 4.58% over the next 12 months. Johnson & Johnson’s current price is $161.60, which has seen a modest gain of 2.07% in the past week but a decline of 3.92% over the last month. Despite the short-term fluctuations, the stock is viewed as stable, with low volatility and high market capitalization.
Positive aspects highlighted in the report include the company’s low debt levels, superior earnings growth over the past five years, and solid returns on assets. However, Johnson & Johnson faces challenges, including below-median total returns over the last five years and lower revenue growth compared to its sector peers.
Conclusion:
As Johnson & Johnson gears up to announce its Q3 financial results, analysts and investors will closely examine its ability to maintain revenue growth despite declining profits. With a slightly bullish outlook from analysts and Stock Target Advisor, Johnson & Johnson is well-positioned for long-term stability, but it must address its revenue growth and profitability challenges to boost investor confidence.
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
